Get startedLog in
    Picture of Disruptive Pharma AB (publ) logo

    DPHA — Disruptive Pharma AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: Guard Therapeutics Announces Positive Results Of Phase 1b Trial

    Picture of Disruptive Pharma AB (publ) logoDisruptive Pharma AB (publ)
    16/03/2023 08:19
    March 16 (Reuters) - Guard Therapeutics International AB
(publ)  GUARD.ST :
    * GUARD THERAPEUTICS PRESENTS POSITIVE CLINICAL DATA WITH
RMC-035
IN PATIENTS UNDERGOING KIDNEY TRANSPLANTATION
    * STUDY MET PRIMARY OBJECTIVE, DEMONSTRATED GOOD
PHARMACOKINETIC
PROPERTIES OF RMC-035 IN THIS PATIENT POPULATION AND A FAVORABLE
SAFETY PROFILE
    * ANNOUNCES POSITIVE RESULTS OF COMPANY'S PHASE 1B CLINICAL
TRIAL

Source text for Eikon:  ID:nMFN4KrrDs 
Further company coverage:  GUARD.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

    Recent news on Disruptive Pharma AB (publ)

    See all news